53 research outputs found
Clinical and Molecular Assessment in a Female with Fragile X Syndrome and Tuberous Sclerosis.
Fragile X syndrome (FXS) and tuberous sclerosis (TSC) are genetic disorders that result in intellectual disability and an increased prevalence of autism spectrum disorders (ASD). While the clinical presentation of each disorder is distinct, the molecular causes are linked to a disruption in the mTORC1 (mammalian Target of Rapamycin Complex 1) and ERK1/2 (Extracellular signal-Regulated Kinase) signaling pathways.
We assessed the clinical and molecular characteristics of an individual seen at the UC Davis MIND Institute with a diagnosis of FXS and TSC. Clinical evaluation of physical, behavioral, and cognitive impairments were performed. Additionally, total and phosphorylated proteins along the mTORC1 and ERK1/2 pathways were measured in primary fibroblast cell lines from the proband.
In this case the phenotypic effects that result in a human with both FXS and TSC are shown to be severe. Changes in mTORC1 and ERK1/2 signaling proteins and global protein synthesis were not found to be noticeably different between four cohorts (typically developing, FMR1 full mutation, FMR1 full mutation and TSC1 loss of function mutation, and TSC1 loss of function mutation); however cohort sizes prevented stringent comparisons.
It has previously been suggested that disruption of the mTORC1 pathway was reciprocal in TSC and FXS double knock-out mouse models so that the regulation of these pathways were more similar to wild-type mice compared to mice harboring a Fmr1(-/y) or Tsc2(-/+) mutation alone. However, in this first reported case of a human with a diagnosis of both FXS and TSC, substantial clinical impairments, as a result of these two disorders were observed. Differences in the mTORC and ERK1/2 pathways were not clearly established when compared between individuals with either disorder, or both
Effect of Recurrent Otitis Media on Language Profile in Children with Fragile X Syndrome
Translating molecular advances in fragile X syndrome into therapy: a review.
Fragile X syndrome is an inherited disease with cognitive, behavioral, and neurologic manifestations, resulting from a single genetic mutation. A variety of treatments that target individual symptoms of fragile X syndrome are currently utilized with limited efficacy. Research in animal models has resulted in the development of potential novel pharmacologic treatments that target the underlying molecular defect in fragile X syndrome, rather than the resultant symptoms. This review describes recent advances in our understanding of the molecular basis of fragile X syndrome and summarizes the ongoing clinical research programs
Surveillance and prevalence of fragile X syndrome in Indonesia
Item does not contain fulltextFragile X syndrome (FXS) is the most prevalent inherited cause of intellectual disability (ID) and autism spectrum disorder (ASD). Many studies have been conducted over the years, however, in Indonesia there is relatively less knowledge on the prevalence of FXS. We reviewed all studies involving FXS screening and cascade testing of the high-risk population in Indonesia for two decades, to elucidate the prevalence, as well as explore the presence of genetic clusters of FXS in Indonesia. The prevalence of FXS in the ID population of Indonesia ranged between 0.9-1.9%, while in the ASD population, the percentage was higher (6.15%). A screening and cascade testing conducted in a small village on Java Island showed a high prevalence of 45% in the ID population, suggesting a genetic cluster. The common ancestry of all affected individuals was suggestive of a founder effect in the region. Routine screening and subsequent cascade testing are essential, especially in cases of ID and ASD of unknown etiology in Indonesia
Deconstructing the attention deficit in fragile X syndrome: a developmental neuropsychological approach
Annotation: Deconstructing the attention deficit in fragile X syndrome: a developmental neuropsychological approach
Epilepsy, and EEG findings in males with fragile X syndrome.
Summary: Purpose and Methods: One hundred and ninetytwo
fragile X male patients were investigated for seizures and
EEG findings, 168 in a retrospective and 24 in another prospective
study, to characterize the natural history of seizures,
epilepsy, and EEG abnormalities in males with this syndrome.
Results: Seizures were documented in 35 (18.2%) of 192
patients; they never started before the age of 2 years or after the
age of 9 years. Seizures were frequently of the complex partial
type and less frequently of the partial motor and generalized
type. Seizures involving frontal and temporal lobes were commonly
seen and were usually well controlled by anticonvulsants.
In the majority of young fragile X patients studied, an
age-related paroxysmal EEG pattern was found, which showed
neurophysiologic characteristics very similar to those of the
centrotemporal spikes.
Conclusions: These findings confirm that fragile X syndrome
can be considered a genetic model of epilepcy
Psychological symptoms correlate with reduced hippocampal volume in fragile X premutation carriers
Fragile-X–Associated Tremor/Ataxia Syndrome (FXTAS) in Females with the FMR1 Premutation
- …